Company news

Neurocrine Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2020 Financial Results

October 5, 2020

Neurocrine Biosciences Announces Once-Daily ONGENTYS® (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes

September 13, 2020

Neurocrine Biosciences Reports Second Quarter 2020 Financial Results

August 2, 2020

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2020 Financial Results

July 12, 2020

Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders

June 15, 2020

Neurocrine Biosciences Exercises Option to License Idorsia's Novel Treatment for Rare Pediatric Epilepsy

May 10, 2020

Neurocrine Biosciences Reports First Quarter 2020 Financial Results

May 5, 2020

Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes

April 26, 2020

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2020 Financial Results

April 14, 2020

Neurocrine Biosciences Provides COVID-19 Business Update

April 2, 2020

Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results

February 3, 2020

Neurocrine Biosciences Announces Appointment of Shalini Sharp to Board of Directors

February 2, 2020

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results

January 19, 2020

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones

January 11, 2020

Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy

January 9, 2020

Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

December 1, 2019

Neurocrine Biosciences Reports Third Quarter 2019 Financial Results

November 3, 2019

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2019 Financial Results

October 13, 2019

Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

October 3, 2019

Neurocrine Biosciences Appoints David W. Boyer as Chief Corporate Affairs Officer

September 29, 2019

Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®

September 16, 2019

Neurocrine Biosciences Announces Appointment of Leslie V. Norwalk to Board of Directors

September 10, 2019

Neurocrine Biosciences Reports Second Quarter 2019 Financial Results

July 28, 2019

Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease

July 9, 2019

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results

July 7, 2019

Neurocrine Biosciences to Present at Jefferies 2019 Global Healthcare Conference

May 29, 2019

Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting

May 4, 2019

Neurocrine Biosciences Reports First Quarter 2019 Financial Results

April 28, 2019

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2019 Financial Results

April 7, 2019

← Newer news releases

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 40 decks. Every deck is listed under its year.